| Anticancer Fund

PRIMMO-study shows poor response to combination treatment for women with cervical or endometrial cancer

Tue, 10/25/2022 - 12:00

A publication by scientists of the Anticancer Fund

Drug repurposing as a potential source of innovative therapies in cervical cancer

Rica Capistrano I, Sonz Paul, Ingrid Boere, Pan Pantziarka, Supriya Chopra, Remi A Nout and Gauthier Bouche. Drug repurposing as a potential source of innovative therapies in cervical cancer. International Journal of Gynecological Cancer, 22 September 2022. doi: 10.1136/ijgc-2022-003585

Tue, 10/11/2022 - 12:00

We support an international call for research proposals in rare cancers

Tue, 10/11/2022 - 12:00

Pembrolizumab, radiotherapy, and an immunomodulatory five‑drug cocktail in pre-treated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden‑Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frédéric Amant, Katrien Vandecasteele, Hannelore G. Denys. Cancer Immunology, Immunotherapy. DOI: 10.1007/s00262-022-03253-x

Tue, 10/04/2022 - 12:00

We join hands to defeat neuroblastoma, a rare cancer that affects children

Mon, 10/03/2022 - 12:00

Patricia Vandamme joins the Anticancer Fund as Policy Officer

Fri, 09/30/2022 - 12:00

We’re improving our information service for cancer patients

Mon, 09/19/2022 - 12:00

‘The Art of Fearless Living’ - Charity Art Experience by Jean-Philippe Demeyer

Fri, 09/02/2022 - 12:00